TCRX CIK: 1783328

TScan Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
166
FY22:
124
FY23:
194
FY24:
293
FY25:
157
(positive)
Change from FY21 to FY25
millions USD
FY21:
22.5
FY22:
75.0
FY23:
77.9
FY24:
78.4
FY25:
71.6
Total assets
Change from FY21 to FY25
millions USD
FY21:
188
FY22:
199
FY23:
272
FY24:
371
FY25:
229

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
21.3
FY22:
17.3
FY23:
29.8
FY24:
36.0
FY25:
18.7
(negative)
Change from FY21 to FY25
millions USD
FY21:
5.99
FY22:
82.4
FY23:
91.5
FY24:
94.2
FY25:
87.0
(positive)
Change from FY21 to FY25
millions USD
FY21:
161
FY22:
99.4
FY23:
151
FY24:
241
FY25:
123
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
188
FY22:
199
FY23:
272
FY24:
371
FY25:
229

All amounts in millions USD Data source:SEC EDGAR